Andrew McConaghie

Andrew McConaghie

Senior Writer

London, UK

Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.

Latest from Andrew McConaghie

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.

Boehringer’s Next Generation IPF Drug Underwhelms

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

Shares are hit as German conglomerate lowers revenue forecast.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.